A Seed in Barren Ground

by

The market, like a hard-scrabble farm, favors the already prosperous. Vertex Pharmaceuticals, a sturdy oak grown thick with the fruit of cystic fibrosis treatments, stands tall. But it’s the tender shoot beside it, CRISPR Therapeutics, that deserves a closer look, a patient hand to nurture its growth. There’s a quiet dignity in this smaller company, a striving that echoes the hopes of those long burdened by illness.

Vertex has reaped a good harvest from Alyftrek, Trikafta, and the like – solid work, to be sure. They predict further bounty from Casgevy, a gene-editing therapy for sickle cell and thalassemia. But the true promise lies not just in easing suffering, but in curing it. And that, friend, is where CRISPR Therapeutics holds the seed.

This Swiss company, CRISPR, birthed Casgevy. They’ve wrestled the very code of life into submission, and for that, they deserve more than a passing glance. They’ll share in the increased sales, yes, but the real reward isn’t measured in dollars, but in the lives touched, the futures reclaimed.

Loading widget...

A Long Row to Hoe

Cathie Wood, a woman who understands the value of a long view, holds a substantial stake in CRISPR through her Ark Innovation ETF. Nearly 6.3% of the fund, second only to Tesla. She sees, as any good farmer does, the potential in the soil. CRISPR isn’t just tinkering around the edges; they’re developing therapies that could rewrite the very story of disease. Five candidates are already in clinical trials, each with the potential to reach more patients than Casgevy alone.

Consider CTX310, a single-treatment therapy for cardiovascular disease. They’ve shown it can reduce triglycerides and LDL cholesterol by over 80%. That’s not just treating the symptom; it’s addressing the root. And CTX320, aimed at atherosclerotic cardiovascular disease, offers another path toward lasting health. There’s also SRSD107, a long-acting therapy for thrombosis, and CTX211, which holds the promise of restoring insulin production in type 1 diabetes patients. These aren’t just drugs; they’re acts of restoration.

The Lean Years

CRISPR isn’t yet profitable, and that’s drawn the vultures. The stock has fallen 64% over the last five years. In 2025, revenue was a mere $3.5 million, a dip from the year before, due to accounting adjustments. They reported a loss of $6.47 per share. But a farmer doesn’t abandon a field after a bad season. They assess, they adapt, they plant again. CRISPR has over $1.9 billion in cash, and if Casgevy gains traction, it will have the resources to nurture its pipeline.

These therapies aren’t cheap. Casgevy carries a list price of $2.2 million per treatment. But can you put a price on a life reclaimed? CRISPR already has the manufacturing and treatment infrastructure in place, a crucial advantage over rivals. It’s a high-risk investment, yes, and volatility is likely. But it’s also a high-potential one, and a company ripe for acquisition.

At its current price, CRISPR Therapeutics is worth a careful look. It’s not just about chasing profits; it’s about investing in a future where illness doesn’t define destiny. It’s about planting a seed in barren ground, and having the faith to see it grow.

Read More

2026-02-20 17:42